One month after Roche’s Genentech inked a similar deal, the Swiss pharma is now paying $50 million to work with Monte Rosa on molecular glue medicines for cancer and neurological diseases.
News Ticker
- [ December 1, 2023 ] Introducing Mundus Mini HD by EQUASHIELD: Redefining the Safe Handling of Hazardous Drugs News
- [ December 1, 2023 ] ARCH-allied AN Venture Partners raises $200M to build biotechs out of research from Japan News
- [ December 1, 2023 ] Potrero Medical Announces Restructuring and Continued Operations News
- [ December 1, 2023 ] Scrum Studio and Hakuhodo Launch AgeTechX to Redefine the Future of Health and Longevity News
- [ December 1, 2023 ] 280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS News
Copyright © 2023 Biotech Networks, LLC
